Business: Phase 3 biotech developing small molecule therapies for Alzheimer's disease. CNFinance Holdings - 6.5 million shares, priced $7.50-$8.50 ...
News
- Initial public offerings scheduled to debut next week
- Texas Biomed CEO charting global course for SA institute
The New Jersey native believes San Antonio can be a global center for infectious disease research with new investment in Texas Biomed's campus.
- Radius Health: 3Q Earnings Snapshot
The biotechnology company posted revenue of $27.6 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected ...
- Agena Launches Bone Marrow Engraftment Assay For Chimerism Analysis
1, 2018 /PRNewswire/ -- Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the Chimeric ID Panel ...
- Former employee buys out owners of animal vaccine plant
He's formed Vos BioTech and intends to retain as many of the plant's employees as possible. When Elanco announced in September last year that it ...